Payment overview · 2025
General Payments
$173.71
9 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Burton, MD
Allopathic & Osteopathic Physicians|Family Medicine · HICKORY, NC · NPI 1083693980
Verified facts
What the public records show
CMS Open Payments records show Michael Burton, MD received $173.71 in general payments during 2025 across 9 reported records.
Abbott Laboratories accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 287 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.93 | 27.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.54 | 15.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.03 | 13.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.02 | 13.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.86 | 10.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.66 | 10.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.67 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.71 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.93 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.02 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 330 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
330 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
287 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 509 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 491 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 456 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 101 |
| Omeprazole | Omeprazole | 339 | 89 |
| Jardiance | Empagliflozin | 330 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 96 |
| Losartan Potassium | Losartan Potassium | 322 | 82 |
| Gabapentin | Gabapentin | 317 | 77 |
| Furosemide | Furosemide | 290 | 73 |
| Eliquis | Apixaban | 287 | 47 |
| Alprazolam | Alprazolam | 235 | 32 |
| Montelukast Sodium | Montelukast Sodium | 233 | 62 |
| Metformin Hcl Er | Metformin Hcl | 230 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 59 |
| Lisinopril | Lisinopril | 197 | 60 |
| Ozempic | Semaglutide | 187 | 35 |
| Ezetimibe | Ezetimibe | 185 | 52 |
| Allopurinol | Allopurinol | 165 | 44 |
| Metformin Hcl | Metformin Hcl | 152 | 47 |
| Clonazepam | Clonazepam | 146 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 142 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 48 |
| Tramadol Hcl | Tramadol Hcl | 142 | 38 |
| Prednisone | Prednisone | 135 | 83 |
| Sertraline Hcl | Sertraline Hcl | 134 | 36 |
| Alendronate Sodium | Alendronate Sodium | 131 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 17 |
| Carvedilol | Carvedilol | 114 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 32 |
| Mirtazapine | Mirtazapine | 108 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 38 |
| Cefuroxime | Cefuroxime Axetil | 98 | 73 |
| Topiramate | Topiramate | 98 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 19 |
| Fluconazole | Fluconazole | 85 | 45 |
| Donepezil Hcl | Donepezil Hcl | 84 | 20 |
| Valsartan | Valsartan | 81 | 20 |
| Bupropion Xl | Bupropion Hcl | 80 | 23 |
| Glimepiride | Glimepiride | 80 | 25 |
| Spironolactone | Spironolactone | 79 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 26 |
| Telmisartan | Telmisartan | 76 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 18 |
| Azithromycin | Azithromycin | 72 | 60 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 21 |
| Trazodone Hcl | Trazodone Hcl | 67 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Famotidine | Famotidine | 58 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 47 |
| Atenolol | Atenolol | 56 | 15 |
| Finasteride | Finasteride | 56 | 16 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 16 |
| Mounjaro | Tirzepatide | 50 | 14 |
| Potassium Chloride | Potassium Chloride | 50 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 12 |
| Ketoconazole | Ketoconazole | 45 | 24 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | 12 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 30 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Cephalexin | Cephalexin | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | 12 |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Diazepam | Diazepam | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 13 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 24 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | 11 |
| Linzess | Linaclotide | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Nateglinide | Nateglinide | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Fetzima | Levomilnacipran Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.71 · 9 records | Abbott Laboratories | AIRSUPRA, FREESTYLE LIBRE 3, JARDIANCE, LINZESS, NURTEC ODT, TRINTELLIX, VIBERZI, VOQUEZNA, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error